Athersys, Inc. (ATHX)
| Market Cap | 319.02M |
| Revenue (ttm) | 1.36M |
| Net Income (ttm) | -93.82M |
| Shares Out | 222.44M |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | 1.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,179,633 |
| Open | 1.43 |
| Previous Close | 1.41 |
| Day's Range | 1.40 - 1.44 |
| 52-Week Range | 1.35 - 3.03 |
| Beta | -1.72 |
| Analysts | Strong Buy |
| Price Target | 5.75 (+302.1%) |
| Est. Earnings Date | Nov 9, 2021 |
About ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ...
Financial Performance
In 2020, Athersys's revenue was $1.44 million, a decrease of -74.44% compared to the previous year's $5.63 million. Losses were -$78.77 million, 76.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for Athersys stock is "Strong Buy." The 12-month stock price forecast is 5.75, which is an increase of 302.10% from the latest price.
News
Are Options Traders Betting on a Big Move in Athersys (ATHX) Stock?
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.
Athersys: Q2 Earnings Insights
Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.10), which w...
Athersys Reports Second Quarter 2021 Results
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys reports Q2 earnings and positive topline ARDS data evaluating MultiStem® from its partner HEALIOS, K.K. The companies advance partnership.
Athersys Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute Respiratory Distress Syndrome...
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Healios announces positive topline clinical data from the ONE-BRIDGE study evaluating MultiStem for acute respiratory distress syndrome (ARDS).
Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership
CLEVELAND & TOKYO--(BUSINESS WIRE)---- $ATHX #Athersys--Healios and Athersys deepen their partnership and improve the collaboration agreement to enhance preparations for commercial activity in Japan.
Athersys to Host Second Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)---- $ATHX #athersys--Athersys to Host Second Quarter Financial Results Call on August 9th, 2021.
New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response i...
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ATHX--Peer-reviewed publication provides evidence of MAPC / MultiStem mechanisms of action on the inflammatory response by promoting Treg differentiation.
Athersys Reports First Quarter 2021 Results
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys reports First Quarter 2021 financial results and will provide a corporate update today at 4:30 PM EDT.
Athersys to Present at the Bank of America Virtual Healthcare Conference on May 12
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Ivor Macleod, CFO of Athersys Inc. is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 12th.
Athersys, Inc. (ATHX) Upgraded to Buy: Here's What You Should Know
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athersys to Host First Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)---- $ATHX #earnings--Athersys, Inc. will host its first quarter 2021 financial results call on Thursday, May 6, 2021 at 4:30 PM EDT.
Athersys to Present at the Needham Virtual Healthcare Conference on April 14
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 14th and the event will be webcast.
Why Athersys Stock Jumped Today
The biotech's partner completed enrollment in a key clinical study.
Athersys Reports That Healios Has Completed Enrollment in the ONE-BRIDGE Study of MultiStem® for Acute Respiratory Di...
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys partner in Japan, HEALIOS KK, completes enrollment in the ONE-BRIDGE study evaluating MulitiStem cell therapy for the treatment of ARDS.
Athersys Announces Financial Results for Fourth Quarter and Full Year 2020
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys continues to develop large-scale manufacturing processes and advance MultiStem cell therapy clinical trials for stroke, ARDS, and trauma.
Athersys to Host Year-End 2020 Financial Results Call
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.
Athersys Announces Cooperation Agreement With HEALIOS K.K.
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.
Athersys Announces CEO Transition
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys
Athersys: Risky Financial Position, But Promising Upside By FYE 2023
Athersys: Risky Financial Position, But Promising Upside By FYE 2023
Athersys to Host a Virtual Investor Day
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.
Athersys (ATHX) Surges: Stock Moves 8.8% Higher
Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem®...
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries
Athersys Announces Three Appointments to Board of Directors
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.